CRISPR Therapeutics (CRSP) PT Lowered to $101 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/18/2024
- Nasdaq, S&P muted as higher bond yields weigh
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Wall St turns higher, gold climbs, oil dips amid economic, geopolitical crosswinds
- US dollar modestly firmer after strong data, Fed comments
- Oil steadies as new sanctions interrupt easing tensions
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Lithium Americas Corp (LAC) Announces Proposed 55M Share Offering
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
CRISPR Therapeutics (CRSP) Appoints Brendan Smith as new CFO
October 14, 2021 7:03 AM EDTCRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Brendan Smith as Chief Financial Officer, effective today. Mr. Smith brings more than 20 years of financial, operational and strategic leadership experience, including as CFO of Translate Bio. He succeeds Michael Tomsicek, who is retiring after four years of service to the Company. It is expected that Mr. Tomsicek will remain with the Company in an advisory role through the end of 2021 to help ensure a smooth transition.
I'm excited to... More
CRISPR Therapeutics (CRSP) Shares Trade Off Despite CTX110 Advancing, Truist Securities Defends
October 13, 2021 6:22 AM EDTTruist Securities analyst Joon Lee reiterated a Buy rating and $220.00 price target on CRISPR Therapeutics (NASDAQ: CRSP) after the company reported a CTX110 trial update AMC that was notable for a 58% overall response (ORR), 38% complete response (CR) and 6-month CR of 21%.
Despite the update, shares traded down for 3 reasons:
DL1... MoreCRISPR Therapeutics (CRSP) Announces Positive Phase 1 Results of CARBON Trial of CTX11 in Relapsed or Refractory CD19+ B-cell malignancies
October 12, 2021 4:02 PM EDTCRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced updated results from the Companys ongoing Phase 1 CARBON trial evaluating the safety and efficacy of CTX110, its wholly-owned allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies.
We are excited to share positive data from our CARBON trial, which show that CTX110 could offer patients with large B-cell lymphomas an immediately available off-the-shelf therapy with efficacy similar to autologous CAR-T and a differentiated safety profile, said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR... More
Cathie Wood's ARK Buys More Teladoc (TDOC), CRISPR (CRSP), Sells ~100K Shares of Coinbase (COIN)
October 12, 2021 6:44 AM EDTCathie Wood's ARK active ETFs bought ~212K shares of Teladoc (NYSE: TDOC) and 248K shares of CRISPR Therapeutics (NASDAQ: CRSP) on Monday, among other buys.
On the sale side, the firm sold 394K shares of Iridium... More
